PTO/SB/21/(09-04) Approved for use through 07/31/2006. OMB 0651-0031

CE ber.

RACE Under the Page	rwork Reduction Act of 1995, no	persons are required	U.S. Patent and to respond to a collection	d Trade	mark Office; U.S. DEPARTMENT OF COMME mation unless it displays a valid OMB control nu
Officer sile i ape			Application Number		10/617,489
Ti	RANSMITT	AL	Filing Date		July 10, 2003
FORM			First Named Invent	tor	Thomas L. CANTOR
			Art Unit		1641
(to be used for all correspondence after initial filing)			Examiner Name		C. Cheu
Total Numbe	r of Pages in This Submiss	ion 10	Attorney Docket Nu	umber	532212000623
	EN	CLOSURES	(Check all that a	apply))
X Fee Transr duplicate)	mittal Form (1 page plus	Drawing(s)			After Allowance Communication to TC
Fee /	Attached	Licensing-rel	ated Papers		Appeal Communication to Board of Appeals and Interferences
Amendmer	nt/Reply	Petition			Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After	Final	Petition to Co Provisional A			Proprietary Information
Affid	avits/declaration(s)		mey, Revocation rrespondence Address	s [Status Letter
Extension	of Time Request	Terminal Disclaimer			X Other Enclosure(s) (please Identify below):
Express Al	bandonment Request	Request for Refund .		(PTO/SB/08a/b (2 pages plus duplicate); 25 references; Return
x Information pages)	n Disclosure Statement (3	CD, Number of CD(s)		_ 1	Receipt Postcard
Certified C	opy of Priority (s)	Landscape Table on CD			
	lissing Parts/ Application	Remarks			
Repl	y to Missing Parts under		CUSTOMER NO.: 25225		NO.: 25225
∟] 37 C	FR 1.52 or 1.53		•		
	SIGNAT	JRE OF APPLICA	ANT, ATTORNEY,	OR A	GENT
Firm Name	MORRISON & FOE			·	
Signature	-	>			
Printed name	Peng Chen	41			
Date September 8, 2006			Reg. I	No.	43,543
7	<u> </u>				
Express Mail, Air Commissioner fo	bill No. EV 915 685 933 US, or Patents, P.O. Box 1450, Alex	on the date shown belo kandria, VA 22313-145	w in an envelope addre:	d) is beir ssed to:	ng deposited with the U.S. Postal Service as MS Amendment (Judy Calem)
Dated: Septembe	si o, 2000	Signature: 4000			_ (000) Oalem)

PTO/SB/17 (01-06)

September 8, 2006

Approved for use through 7/31/2006. OMB 0651-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known ursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). 10/617,489 **Application Number** FEE TRANSMITTAL July 10, 2003 Filing Date For FY 2006 Thomas L. CANTOR First Named Inventor **Examiner Name** C. Cheu 1641 Applicant claims small entity status. See 37 CFR 1.27 Art Unit 532212000623 **TOTAL AMOUNT OF PAYMENT** 180.00 Attorney Docket No. METHOD OF PAYMENT (check all that apply) Money Order None Other (please identify): Check Credit Card Morrison & Foerster LLP X Deposit Account Deposit Account Number: 03-1952 Deposit Account Name: For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below, except for the filing fee x Charge fee(s) indicated below Charge any additional fee(s) or underpayment of Credit any overpayments fee(s) under 37 CFR 1.16 and 1.17 FEE CALCULATION (All the fees below are due upon filing or may be subject to a surcharge.) 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES Small Entity Small Entity** Small Entity Fees Paid (\$) Fee (\$) Fee (\$) **Application Type** Fee (\$) Fee (\$) Fee (\$) Fee (\$) 300 150 500 250 200 100 Utility 130 65 200 100 100 50 Design Plant 200 100 300 150 160 80 600 300 150 500 250 300 Reissue 0 0 0 Provisional 200 100 0 Small Entity 2. EXCESS CLAIM FEES Fee (\$) Fee (\$) Fee Description 50 25 Each claim over 20 (including Reissues) Each independent claim over 3 (including Reissues) 200 100 180 360 Multiple dependent claims **Multiple Dependent Claims Total Claims** Extra Claims - 101 Fee Paid (\$) Fee (\$) HP = highest number of total claims paid for, if greater than 20. Fee Paid (\$) Indep. Claims Extra Claims HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Fee Paid (\$) Number of each additional 50 or fraction thereof Fee (\$) Extra Sheets **Total Sheets** _____ (round up to a whole number) x ____ - 100 = _____ Fees Paid (\$) 4. OTHER FEE(S) Non-English Specification, \$130 fee (no small entity discount) 180.00 Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement SUBMITTED BY Registration No. Telephone 43,543 (858) 720-5117 Signature (Attorney/Agent) Date

ed.	22/	1598

Name (Print/Type)

Peng Chen

SEP. 0 8 2006 BE

Priereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 915 685 933 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 8, 2006 Signature:

Patent Docket No. 532212000623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Thomas L. CANTOR et al.

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES

FOR DETECTING PARATHYROID

HORMONE

Examiner: C. Cheu

Group Art Unit: 1641

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Document numbers 7-14 are from the Reexamination proceeding of U.S. Patent No. 6,030,790, having Control No. 90/007,412. Document numbers 15-18 are updated court dockets downloaded from PACER for the litigation matters that the patent owner is a party. Document numbers 19 and 20 are from Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc. and Scantibodies Laboratory, Inc., currently pending in the United States Court of Appeals for

09/13/2006 RMEBRAHT 0000032 031952

the Federal Circuit, Case No. 06-1443. Document number 21 is from *Nichols Institute Diagnostics*, *Inc. v. Scantibodies Clinical Laboratory Inc. and Scantibodies Laboratory, Inc.*, U.S.D.C. for the Southern District of California, Case No. 02 CV 0046 B (LAB), currently on appeal at the United States Court of Appeals for the Federal Circuit, Case No. 06-1087. Document numbers 22-25 are from the Reexamination proceeding of US Patent No. 6,689,566, having Control Numbers 90/007,685 and 90/007,732. The present application is a Continuation-in-Part (CIP) of US Patent No. 6,743,590, which is a CIP of US Patent No. 6,689,566.

This Information Disclosure Statement is submitted:

	With t	he application; accordingly, no fee or separate requirements are required.
	Before	the mailing of a first Office Action after the filing of a Request for Continued
	Exami	nation under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1)	has been provided.
	Withir	three months of the application filing date or before mailing of a first Office Action
	on the	merits; accordingly, no fee or separate requirements are required. However, if
	applica	able, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
\boxtimes	After 1	receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Not	ice of Allowance.
		A fee is required. A check in the amount of is enclosed.
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
		this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
		believed to be due.
	After 1	nailing of a final Office Action or Notice of Allowance, but before payment of the
	issue f	ee.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000623.

Dated: September 8, 2006

Respectfully submitted,

Peng Chen

By

Registration No.: 43,543 MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040

(858) 720-5117

SEP'U & 2006 W.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known			
Application Number	10/617,489			
Filing Date	July 10, 2003			
First Named Inventor	Thomas L. CANTOR			
Art Unit	1641			
Examiner Name	C. Cheu			
Attorney Docket Number	532212000623			

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

		FOREIC	ON PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1.	JENSEN et al., Clinical Chemistry (1996) 42(6):S172 Abstract 320 "Comparing Specificity For Intact Human Parathyroid Hormone Between INCSTAR PTHSP and Nichols Intact PTH Assays"	
	2.	D'AMOUR, Kidney International (2006) 70:S29-S33	
	3.	D'AMOUR et al., Kidney International (2005) 68:998-1007	
	4.	GARDELLA et al., J. Biol. Chem. (1995) 270:6584-6588	
	5.	HUAN et al., J. Am. Soc. Nephrol. (2006) 17:1923-1930	
	6.	KUNII and VIEIRA, Braz. J. Med. Biol. Res. (2001) 34(12):1547-1550	
	7.	Amendment and Reply Under 37 C.F.R. § 1.116, filed July 10, 2006, from the Reexamination of U.S. Patent No. 6,030,790, Control No. 90/007,412	
	8.	Ex Parte Reexamination Advisory Action, mailed August 3, 2006	
	9.	Communication and Request For An Interview, filed August 8, 2006	
	10.	Petition For An Extension of Time, filed August 8, 2006	
	11.	Statement of Substance of Interview Under 37 CFR § 1.560(b), filed August 9, 2006	
	12.	Miscellaneous Communication, filed August 11, 2006	
	13.	Amendment and Reply Under 37 CFR 1.116 and Statement of Substance of Interview Under 37 CFR § 1.560(b), filed August 16, 2006	
	14.	Ex Parte Reexamination Interview Summary, mailed August 16, 2006	
	15.	Court Docket from PACER for Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc., from the US District Court for the Southern District of California, docket accessed September 8, 2006 (for 2006 dates only)	
	16.	Court Docket from PACER for Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical Laboratory, Inc., from the US Court of Appeals for the Federal Circuit, Case No. 06-1087, docket accessed September 8, 2006	
	17.	Court Docket from PACER for Nichols Institute Diagnostics, Inc. v. Scantibodies Clinical	

Examiner	Date	
Signature	Considered	

		T0		Complete if Known		
Sut	ostitute for form 1449/P	10		Application Number	10/617,489	
11	VEORMATI	ON DI	SCLOSURE	Filing Date	July 10, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Thomas L. CANTOR	
~	//AILINEIN		AI I LIOAIII	Art Unit	1641	
	(Use as man	y sheets as	necessary)	Examiner Name	C. Cheu	
Sheet	2	of	2	Attorney Docket Number	532212000623	

	Laboratory, Inc., from the US Court of Appeals for the Federal Circuit, Case No. 06-1443, docket accessed September 8, 2006
18.	Court Docket from PACER for Scantibodies Laboratory, Inc., v. Immutopics, Inc., from the US District Court for the Central District of California, docket accessed September 8, 2006
19.	Appellant Nichols Institute of Diagnostics, Inc.'s Opening Brief, US Court of Appeals for the Federal Circuit, Case No. 06-1443, filed August 22, 2006
20.	Appellant Nichols Institute of Diagnostics, Inc.'s Corrected Opening Brief, US Court of Appeals for the Federal Circuit, Case No. 06-1443, filed August 30, 2006
21.	
22.	Office Action in Ex Parte Reexamination of US Patent No. 6,689,566, Control No.'s 90/007,685 and 90/007,732, mailed on May 24, 2006
23.	
24.	Ex Parte Reexamination Interview Summary, July 10, 2006
25.	Amendment in Response to Non-Final Office Action (and Exhibits 1-12 and Replacement Sheet Figure 5), filed in the Ex Parte Reexamination of US Patent No. 6,689,566, Control No.'s 90/007,685 and 90/007,732, filed on July 24, 2006

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.